MedPath

Famotidine

Generic Name
Famotidine
Brand Names
Duexis, Duo Fusion, Fluxid, Good Sense Acid Reducer, Pepcid, Pepcid Complete, Zantac Reformulated Aug 2022
Drug Type
Small Molecule
Chemical Formula
C8H15N7O2S3
CAS Number
76824-35-6
Unique Ingredient Identifier
5QZO15J2Z8
Background

Famotidine is a competitive histamine-2 (H) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than cimetidine and eight times more potent than ranitidine on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.

Indication

Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy.

It is also indicated in adult patients for the treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasias) and reduction of the risk of DU recurrence.

The intravenous formulation of famotidine is available for some hospitalized patients with pathological hypersecretory conditions or intractable ulcers or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication.

Over-the-counter famotidine is used for the management and prevention of heartburn caused by gastroesophageal reflux in children and adults. Off-label uses of famotidine include the reduction of NSAIDs-associated gastrointestinal effects, treatment of refractory urticarial, prevention of stress ulcer in critically-ill patients, and symptomatic relief of gastritis.

Associated Conditions
Chronic Back Pain, Duodenal Ulcer, Erosive Esophagitis, Extra-Articular Rheumatism, Gastritis, Heartburn, Helicobacter Pylori Infection, Multiple Endocrine Neoplasia, Muscle Spasms, Nonspecific Pain Post Traumatic Injury, Osteoarthritis (OA), Postoperative pain, Stress Ulcers, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Active Gastric ulcer, Acute Duodenal Ulcers, Gastrointestinal ulceration, Pathological hypersecretory conditions

Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor

Phase 2
Completed
Conditions
Acute Kidney Injury
Interventions
First Posted Date
2023-12-04
Last Posted Date
2025-05-02
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
100
Registration Number
NCT06154226
Locations
🇺🇸

The University of Texas Health Science Center at Houston, Houston, Texas, United States

A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

Phase 1
Terminated
Conditions
Healthy Participants
Interventions
First Posted Date
2023-11-22
Last Posted Date
2025-02-06
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
267
Registration Number
NCT06144697
Locations
🇺🇸

Local Institution - 0003, Austin, Texas, United States

🇺🇸

Local Institution - 0001, Anaheim, California, United States

A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2023-09-26
Last Posted Date
2024-11-13
Lead Sponsor
PMV Pharmaceuticals, Inc
Target Recruit Count
28
Registration Number
NCT06054464
Locations
🇺🇸

Parexel International, Baltimore, Maryland, United States

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Phase 2
Recruiting
Conditions
Carcinomatosis
Gastric Adenocarcinoma
Interventions
First Posted Date
2023-08-07
Last Posted Date
2025-03-07
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT05977998
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Multimodal Pain Package vs. Regular Formulation for Pain Management in Ambulatory Spinal Surgery

First Posted Date
2023-07-28
Last Posted Date
2024-06-21
Lead Sponsor
University of Miami
Target Recruit Count
100
Registration Number
NCT05965492
Locations
🇺🇸

university of Miami, Miami, Florida, United States

🇺🇸

University of Miami, Miami, Florida, United States

Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

First Posted Date
2023-07-14
Last Posted Date
2024-08-21
Lead Sponsor
Emory University
Target Recruit Count
5
Registration Number
NCT05946551
Locations
🇺🇸

Grady Health System, Atlanta, Georgia, United States

🇺🇸

Emory Hospital, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

and more 1 locations

A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants

Phase 1
Recruiting
Conditions
Healthy Volunteers
Interventions
First Posted Date
2023-05-19
Last Posted Date
2025-01-22
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
76
Registration Number
NCT05866627
Locations
🇬🇧

Quotient Sciences, Nottingham, Nottinghamshire, United Kingdom

A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2022-10-31
Last Posted Date
2024-12-12
Lead Sponsor
Amgen
Target Recruit Count
14
Registration Number
NCT05599828
Locations
🇺🇸

Covance Clinical Research Unit, Inc, Dallas, Texas, United States

Gastrointestinal Dysmotility on Aspiration Risk

Phase 4
Not yet recruiting
Conditions
Esophageal Motility Disorders
Gastric Motor Dysfunction
Gastro Esophageal Reflux
Aspiration Pneumonia
Interventions
First Posted Date
2022-07-13
Last Posted Date
2022-07-13
Lead Sponsor
Boston Children's Hospital
Target Recruit Count
120
Registration Number
NCT05455359

Famotidine in Covid-19 Intensive Care Unit

Completed
Conditions
COVID-19 Pandemic
Interventions
First Posted Date
2021-11-16
Last Posted Date
2022-04-19
Lead Sponsor
Istanbul Medeniyet University
Target Recruit Count
60
Registration Number
NCT05122208
Locations
🇹🇷

Istanbul Medeniyet University, İ̇stanbul, Turkey

© Copyright 2025. All Rights Reserved by MedPath